oncology

Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology

Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicinesTORONTO, Jan. 21, 2026 /PRNewswire/ --…

1 day ago

BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions

Reshaping the Global Drug Development Landscape with the Industry's Only Natively AI-Powered Omnimodal Foundation Model for Tumor and Immune BiologySAN…

1 week ago

Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology

CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ -- Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and…

2 weeks ago

American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research

Global oncology society calls for abstract submissions for research that is shaping the future of cancer care in advance of…

2 months ago

Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs

Accomplished biotech and CRO leader brings 25+ years of global oncology drug development and operational excellence to propel Emerald's continued…

2 months ago

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

November 21, 2025 16:30 ET  | Source: Olema Oncology SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”,…

2 months ago

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

November 18, 2025 16:51 ET  | Source: Olema Oncology SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.…

2 months ago

Olema Oncology to Participate in Upcoming Investor Conferences

November 03, 2025 16:30 ET  | Source: Olema Oncology SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”,…

3 months ago

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response…

3 months ago

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress

October 19, 2025 10:00 ET  | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…

3 months ago